MannKind Corp

2026. g. 9. sept. 20:01 UTC

MannKind Corp shares are lower after announcing a licensing deal with Rose Pharma for the development of ROSE-010, an inhaled GLP-1 receptor agonist.

2026. g. 8. sept. 20:07 UTC

MannKind Corp's shares are higher today amid mixed analyst ratings, including a downgrade from Zacks and a price target increase from Royal Bank of Canada.

2026. g. 4. sept. 19:36 UTC

MannKind Corp's shares are advancing, recovering from earlier volatility. The stock is currently above its 20-day moving average amid a stable one-month trading range.

2026. g. 3. sept. 23:26 UTC

MannKind Corp shares are higher in after-market trading, reflecting broader market strength amid reduced rate hike expectations. Major indices reported substantial gains.

2026. g. 1. sept. 20:08 UTC

MannKind Corp's shares are lower amid a broader market downturn and rising oil prices, which have heightened inflation concerns and interest rate hike expectations.

2026. g. 31. aug. 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

2026. g. 28. aug. 20:07 UTC

MannKind Corp shares are lower today, extending a three-day decline amid rising U.S. Treasury yields and broader equity market concerns.

2026. g. 27. aug. 19:46 UTC

MannKind Corp. shares are trading roughly flat, with no specific news identified. The stock remains around the middle of its one-month trading range.

2026. g. 26. aug. 20:56 UTC

MannKind Corp shares are higher in after-market trading, reflecting unusual activity. The stock is significantly above its 20-day moving average.

2026. g. 21. aug. 19:41 UTC

MannKind Corp. shares are lower today, trading near the lower end of their one-month range while above the 20-day moving average.

2026. g. 20. aug. 19:51 UTC

MNKD lower today amid declines in the biotechnology sector.

2026. g. 19. aug. 23:02 UTC

MannKind Corp shares are lower in after-market hours, continuing a downward trend amid broader declines in the biotechnology sector.

2026. g. 18. aug. 22:51 UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified. Broader market sentiment is impacted by rising sovereign bond yields.

2026. g. 17. aug. 19:46 UTC

HC Wainwright lowered Q3 2026 EPS estimates for MannKind Corp to -$0.10 but maintained a “Buy” rating. Shares are higher since Friday's close.

2026. g. 14. aug. 19:56 UTC

MannKind Corp. shares are higher today, reversing a four-session decline despite a broader market influenced by a drop in U.S. retail sales.

2026. g. 13. aug. 19:01 UTC

MannKind Corp's shares are lower Thursday, continuing a five-day decline amid mixed economic signals and no specific news identified to explain the drop.

2026. g. 12. aug. 20:06 UTC

MannKind Corp shares are lower today, continuing a decline since Tuesday's close amid shifting U.S. Treasury yields and broader market uncertainties.

2026. g. 11. aug. 23:46 UTC

MannKind shares are higher in after-market trading, reflecting a slight recovery amid a cautious market ahead of the upcoming consumer price index report.

2026. g. 10. aug. 22:56 UTC

MannKind Corp shares are higher in after-market hours following Monday's close, though no specific news was identified to explain the price movement.

2026. g. 7. aug. 23:01 UTC

MannKind Corp shares declined in after-market trading, reflecting notable weakness despite remaining above the 20-day moving average. No specific news was identified.

2026. g. 6. aug. 22:01 UTC

MannKind Corp shares are lower in after-market trading, reflecting broader market weakness and trading below their 20-day moving average. No specific news was identified.

2026. g. 5. aug. 23:02 UTC

MannKind Corp shares declined after-hours following a second-quarter earnings miss, despite reporting revenues of $109.4 million and FDA approvals for new products.

2026. g. 4. aug. 23:26 UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified to explain the price movement. Trading has remained within a narrow range.

2026. g. 3. aug. 22:51 UTC

MannKind Corp shares are higher in after-market trading, reflecting momentum since Monday's close amid falling Brent crude oil prices and positive market sentiment.

2026. g. 31. jūl. 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

2026. g. 30. jūl. 18:41 UTC

Wells Fargo raised MannKind's price target to $14.00, contributing to positive momentum. The company also reported favorable Phase 1b study results today.

2026. g. 29. jūl. 19:47 UTC

MannKind Corp reported positive results from its Phase 1b INFLO-1 study, but shares are trading lower amid broader market uncertainty ahead of the Fed's decision.

2026. g. 28. jūl. 21:01 UTC

MannKind Corp will report its second quarter 2026 financial results on August 5, 2026. Shares are trading higher in after-market hours.

2026. g. 27. jūl. 22:06 UTC

MannKind Corp shares are higher in after-market trading, despite earlier declines. No specific news was identified to explain the price movement.

2026. g. 24. jūl. 21:01 UTC

MannKind Corp shares are rising in after-market trading following FDA approval of Furoscix ReadyFlow™ for treating edema in heart failure and chronic kidney disease.